Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Other Working Capital Changes: 2015-2024

Historic Other Working Capital Changes for Corvus Pharmaceuticals (CRVS) over the last 10 years, with Dec 2024 value amounting to $1.6 million.

  • Corvus Pharmaceuticals' Other Working Capital Changes rose 81.50% to -$64,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 million, marking a year-over-year increase of 146.30%. This contributed to the annual value of $1.6 million for FY2024, which is 229.34% up from last year.
  • Corvus Pharmaceuticals' Other Working Capital Changes amounted to $1.6 million in FY2024, which was up 229.34% from -$1.2 million recorded in FY2023.
  • Corvus Pharmaceuticals' Other Working Capital Changes' 5-year high stood at $1.6 million during FY2024, with a 5-year trough of -$1.3 million in FY2021.
  • Over the past 3 years, Corvus Pharmaceuticals' median Other Working Capital Changes value was -$1.0 million (recorded in 2022), while the average stood at -$228,667.
  • As far as peak fluctuations go, Corvus Pharmaceuticals' Other Working Capital Changes slumped by 252.28% in 2021, and later spiked by 229.34% in 2024.
  • Yearly analysis of 5 years shows Corvus Pharmaceuticals' Other Working Capital Changes stood at $878,000 in 2020, then crashed by 252.28% to -$1.3 million in 2021, then grew by 21.77% to -$1.0 million in 2022, then decreased by 17.30% to -$1.2 million in 2023, then surged by 229.34% to $1.6 million in 2024.